Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

Aachen, Germany, & Morristown, N.J., 7 November 2024 (News Aktuell) – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical ...

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

Since then, she’s been experiencing continued neuropathy that involves itchiness, a sense of desperation, and some pain.

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

MIRA Pharmaceuticals (MIRA) announces new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...